Opus Genetics (IRD) Change in Cash (2010 - 2026)

Opus Genetics (IRD) has reported Change in Cash for 17 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 29.61% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $18.2 million (up 438.37% YoY), while the FY2025 annual figure was $14.8 million, up 173.19% from the prior year.
• Change in Cash climbed to $14.9 million in Q1 2026 per IRD's latest filing, from $14.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $28.8 million in Q4 2022 and bottomed at -$9.4 million in Q2 2025.
• Historically, Change in Cash has averaged $2.1 million across 5 years, with a median of -$2.2 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Cash soared 1160.03% — and 2024, when it tumbled 681.6%.
• Opus Genetics' Change in Cash stood at $28.8 million in 2022, then tumbled by 71.68% to $8.2 million in 2023, then slumped by 177.43% to -$6.3 million in 2024, then surged by 326.21% to $14.3 million in 2025, then rose by 4.15% to $14.9 million in 2026.
• Business Quant data shows IRD's Change in Cash at $14.9 million in Q1 2026, $14.3 million in Q4 2025, and -$1.6 million in Q3 2025.